Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EPS (Weighted Average and Diluted) (2020 - 2025)

RxSight's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.22 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 46.67% year-over-year to -$0.22; the TTM value through Dec 2025 reached -$0.95, down 31.94%, while the annual FY2025 figure was -$0.95, 33.8% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.22 in Q4 2025 per RXST's latest filing, up from -$0.24 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2021 to a low of -$3.53 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.51, with a median of -$0.29 recorded in 2025.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 82.72% in 2022 against a maximum downside of 711.11% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.09 in 2021, then plummeted by 711.11% to -$0.55 in 2022, then surged by 54.55% to -$0.25 in 2023, then soared by 40.0% to -$0.15 in 2024, then tumbled by 46.67% to -$0.22 in 2025.
  • Per Business Quant, the three most recent readings for RXST's EPS (Weighted Average and Diluted) are -$0.22 (Q4 2025), -$0.24 (Q3 2025), and -$0.29 (Q2 2025).